Search results
PROMOTED
Author(s):
Nicolas M Van Mieghem
,
Kendra J Grubb
,
David Hildick-Smith
,
et al
Start date:
Mar 26, 2024
Author(s):
Ed Soltesz
Added:
1 year ago
Author(s):
David L Joyce
Added:
1 year ago
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
2 years ago
Learn more about of the top AHA 2021 late-breaking trialswith View from the Thoraxcenter hosts, Professor Nicolas Van Mieghem and DrJoost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL). In this short summary video, they summarise the take-home messages and share their take on how the data will shape patient care and research.
Trials covered in detail include:
• Aortic Valve Replacement versus…
View more
Author(s):
Stuart J Head
,
Ad JJC Bogers
,
A Pieter Kappetein
Added:
3 years ago
Abstract
In many patients, comparable results can be achieved either with coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). The comparison of PCI versus CABG is frequently reported in randomised trials, national registries, multicentre collaborations and single-centre experiences. However, the patients included in these analyses are either highly selected …
View more
Author(s):
Edward McNulty
Added:
3 years ago
The debate over the optimal mode of revascularisation for unprotected left main (ULM) coronary artery disease intensified with the advent of drug-eluting stents (DES). Professional society guidelines addressing ULM disease have been revised at an increasing frequency,1,2 the significance of randomised comparisons has been variously interpreted, and observational comparisons have become a…
View more
Kendra J Grubb
Research Area(s) / Expertise:
Job title: Surgical Director
Author
Author(s):
William Fearon
Added:
2 years ago
In this short interview, Dr William F Fearon (Stanford University School of Medicine, US) discusses the findings from the FAME3 trial. This multicenter, international, randomized, controlled noninferiority trial investigated whether fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (CAD) will result in similar…
View more
Author(s):
Frederik Zimmermann
Added:
2 years ago
In this late-breaking interview from ACC.22, Dr Frederik Zimmermann (Catharina Hospital, NL) outlines the main findings of the FAME 3 Trial.
FAME 3 is an international, randomised multicentre trial, that aims to compare the outcomes of fractional flow reserve (FFR)-guided PCI and Coronary Artery Bypass Graft Surgery (CABG) in patients with multivessel coronary artery disease. The results…
View more
Author(s):
Nicolas M Van Mieghem
,
Azeem Latib
,
Kendra J Grubb
,
et al
Start date:
Mar 15, 2023